AI in Pathology Patent Landscape Analysis Report 2026 Edition

AI in Pathology Market Size, Growth Trends, and Industry Outlook

Pathology sits at the centre of cancer diagnosis, and the work is changing as laboratories replace glass slides with digital images that software can read. Pathologist workforces have not kept pace with biopsy volumes, so laboratories are looking for tools that triage cases, flag suspicious regions and standardise the scoring of stained tissue. Adoption has moved from pilot projects in academic centres to routine use in hospital networks and large reference laboratories, helped by regulatory clearance of whole slide imaging systems for primary diagnosis. Pharmaceutical sponsors add a second source of demand, since quantitative tissue analysis supports patient selection and trial endpoints. Cytology screening, molecular reporting and laboratory system integration extend the opportunity beyond histology alone.

Market growth is driven by the shift of laboratories to digital workflows, which creates the scanned image archives that algorithms need and allows cases to be routed across sites without moving glass slides. The FDA cleared the first whole slide imaging system for primary diagnosis in 2017, and an artificial intelligence prostate cancer detection software received De Novo authorisation in 2021, which together showed that a regulated path exists for both image capture and algorithmic assistance. Global cancer incidence of roughly 20 million new cases in 2022 keeps biopsy and resection workloads rising, and every added specimen brings slides that need expert review. Growth runs high for a diagnostics segment because the installed base of clinical algorithms is still small, so each new clearance adds proportionally more.

Cervical cancer accounted for around 660,000 new cases and about 350,000 deaths worldwide in 2022, and because most deaths occur where cytology screening is limited, algorithm-assisted slide reading is attractive for under-resourced programmes. Prostate cancer, with about 1.5 million new diagnoses a year, generates large volumes of core needle biopsies in which tumour may occupy only a few millimetres, which explains why prostate detection software became an early regulatory target. Breast cancer, at roughly 2.3 million new cases annually, drives demand for HER2, oestrogen receptor and Ki-67 scoring, where variation between readers can change treatment selection. Each of these workloads rewards software that reads slides consistently, and laboratories that digitise for one use tend to buy scanners, platforms and analysis licences together.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

AI in Pathology Patent Filing Trends and Innovation Activity

Filing intensity has risen steadily as scanner makers, diagnostics companies and software developers protect work on image acquisition, model training and laboratory integration. Roche, Philips, Leica Biosystems and Hamamatsu Photonics pair instrument portfolios with software claims, while Proscia and other platform vendors file on case management and algorithm hosting. Commercial investment is visible in large reference laboratory deployments, pharmaceutical partnerships for companion diagnostic scoring and venture funding of pathology start-ups. New filings have typically followed those investments within one to two years.

The landscape comprises more than 4,300 patent families, with filing activity peaking between roughly 2021 and 2024 as digital pathology programmes expanded and regulatory clearances accumulated. Leading technology clusters are whole slide scanning and image quality control, tumour detection and grading models, and biomarker and immunohistochemistry scoring. Cytology screening support, digital pathology workflow and laboratory system integration, and molecular and genomic pathology reporting form a second tier that has grown fastest in recent years.

Rising biopsy volumes, pathologist shortages and the spread of digital laboratories have created paying demand for scanners, platforms and diagnostic algorithms, and patent filings have expanded in step with that demand.

Scope of the AI in Pathology Patent Landscape Analysis Report

The scope covers patent filings at the United States, European, Chinese, Japanese, South Korean and Indian offices and through the WIPO Patent Cooperation Treaty route, together with commercial activity in North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Market coverage runs from 2025 through 2035 and includes software licences, scanner-embedded algorithms and integration services sold to hospitals, laboratories and research organisations. Filings are grouped by pathology discipline, solution type and application, and by the six technology clusters identified for the field.

Technology coverage spans Anatomic and Surgical Pathology, Cytopathology, Molecular Pathology, Haematopathology and Clinical Laboratory Pathology. Product coverage includes Whole Slide Imaging Analysis Software, Digital Pathology Workflow Platforms, Slide Scanners with Embedded Algorithms and Laboratory Information System Integration Tools. Applications examined range from Primary Diagnosis Support and Tumour Grading and Biomarker Scoring to Quality Assurance and Second Opinion, Pharmaceutical Research and Trials, and Pathology Education and Training. Methods include deep learning for tumour detection, automated immunohistochemistry quantification, cytology slide triage, and reporting that links tissue findings with genomic results.

Entities include scanner and instrument manufacturers such as Roche, Philips, Leica Biosystems and Hamamatsu Photonics, and digital pathology software specialists such as Proscia. Computational pathology start-ups developing cancer detection and biomarker models, and diagnostics companies that integrate image analysis with assays, are also represented. Academic medical centres, cancer research institutes and clinical laboratories contribute method patents and validation studies, and pharmaceutical and biotechnology companies appear where tissue image analysis supports trial endpoints and companion diagnostics.

Global AI in Pathology Patent Landscape Analysis

AI in Pathology Patent Filing Trend Analysis

Annual filings have grown consistently since the first whole slide imaging clearances in the United States, with the strongest acceleration coming after laboratories began to digitise at scale. Early patents concentrated on scanner optics, focus control and image compression. Later filings moved toward trained models, stain normalisation, case routing and links between image findings and laboratory records, reflecting a field that has shifted from hardware to software value.

Annual patent filing growth between 2020 and 2024 is estimated at approximately 18 percent. Several factors drove it: the pandemic-era acceleration of remote slide review, regulatory clearances for primary diagnosis, wider availability of annotated slide archives, and pharmaceutical demand for quantitative biomarker scoring. Deep learning methods for tumour detection and grading contributed the largest share of the additional filings.

Leading Companies and Assignee Analysis in the AI in Pathology Patent Landscape

Geographic Analysis of AI in Pathology Patent Activity

The report assesses patent activity across major jurisdictions, including:

• United States
• Europe
• China
• Japan
• South Korea
• India
• International and WIPO filings

The United States leads on filing volume because of its early regulatory clearances, large laboratory networks and active computational pathology start-ups. China ranks second, with rapid growth in hospital-led and university-led filings on tumour detection, cytology screening and slide scanning. Europe, including the European Patent Office and national offices in Germany, the Netherlands and the United Kingdom, reflects the strength of Philips, Roche and Leica Biosystems and several national digital pathology programmes. South Korea contributes filings from companies working on cancer detection software, India shows growing activity linked to large laboratory chains and screening programmes, and WIPO filings indicate applicants seeking protection in several regions at once.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

AI in Pathology Technology Segmentation and Innovation Areas

Patent activity in the field falls into five technology segments:

• Whole slide scanning and image acquisition
• Tumour detection and grading algorithms
• Immunohistochemistry and biomarker scoring
• Cytology screening and slide triage
• Digital workflow and laboratory system integration

Tumour detection and grading algorithms lead patent activity, because cancer diagnosis is the main clinical use of digitised slides and the first area in which regulators cleared algorithmic assistance. Applicants file on convolutional and transformer-based models, annotation methods and performance claims for cancers such as prostate, breast and lung. Biomarker scoring ranks next, supported by commercial demand from companion diagnostic programmes.

Competitive Landscape and Emerging Trends in the AI in Pathology Market

Competition combines established diagnostics and imaging groups with specialist software developers. Roche, Philips, Leica Biosystems and Hamamatsu Photonics supply scanners and bundle them with image management, while Proscia and similar vendors compete on platform flexibility and algorithm marketplaces. Computational pathology start-ups focus on narrow clinical claims, often for prostate, breast or lung cancer, and partner with scanner makers for distribution. Companies with regulatory clearance for primary diagnosis hold an advantage in hospital tenders, because buyers prefer systems that are validated end to end.

Companies are focusing on:

• Embedding quality checks in slide scanners
• Training tumour detection models
• Standardising biomarker scoring for companion diagnostics
• Hosting third-party algorithms on open platforms
• Connecting pathology images to laboratory systems
• Supporting cytology screening at scale
• Linking histology images with genomic data

Emerging themes include foundation models trained on very large collections of unlabelled slides, which reduce the annotation effort needed for each new task. Virtual staining, which predicts special stains from routine haematoxylin and eosin images, is attracting claims aimed at saving laboratory time and reagents. Multimodal models that combine tissue images with genomic and clinical data are gaining attention in oncology, and federated learning methods address the difficulty of sharing slides across institutions. FDA guidance on predetermined change control plans for software that learns over time is also shaping how applicants draft claims on model updating.

Strategic Insights from the AI in Pathology Patent Landscape

Patent data on this field shows how scanner makers, diagnostics groups and software developers are dividing territory across image capture, analysis and workflow. Filing patterns indicate which cancers, stains and laboratory tasks attract the most protection, and which jurisdictions applicants consider commercially important. Readers can trace the position of each leading assignee, the pace of new entrants and the areas where claims are still sparse.

The patent landscape provides actionable intelligence for the following nine strategic uses:

• Intellectual property strategy for pathology software
• R&D prioritisation across scanners and algorithms
• Competitive benchmarking of leading assignees
• Technology scouting for detection and scoring models
• Licensing evaluation of algorithm and scanner patents
• Partnership assessment with laboratories and developers
• Investment analysis of pathology software companies
• Market entry planning by jurisdiction
• Portfolio expansion strategy for platform vendors

Research Methodology for the AI in Pathology Patent Landscape Analysis

Patent research was conducted across the major patent databases, including the United States Patent and Trademark Office, the European Patent Office, the China National Intellectual Property Administration, the Japan Patent Office, the Korean Intellectual Property Office, the Indian patent office and WIPO. Searches combined cooperative patent classification codes, keywords and assignee names relating to pathology image analysis, slide scanning, cytology, immunohistochemistry scoring and laboratory workflow software. Patent families were assembled so that each invention was counted once across jurisdictions.

Retrieved records were screened for relevance to pathology, and duplicate families and filings with no connection to tissue, cell or laboratory specimen analysis were removed. Remaining families were classified by pathology discipline, solution type, application and technology cluster, and assigned to assignees after harmonising company names and subsidiaries. Filing years, grant status and jurisdiction were recorded for each family to support trend and concentration measures.

Market analysis drew on published regulatory clearances, company disclosures, clinical literature and cancer statistics to relate patent activity to commercial demand. Estimates for growth rates, peak filing periods and relative shares are analyst approximations built from the classified patent set. Findings were checked for consistency between market projections and observed filing trends before the final assessment.

Related Reports

AI in Pathology Market

Digital Pathology Patent Landscape Analysis Report

Companion Diagnostics Patent Landscape Report